Compare Novartis AG (NVS) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Williams-Sonoma, Inc. — how do they compare? Novartis AG trades at $143.75 (market cap $268.57B), while Williams-Sonoma, Inc. trades at $241.16 (market cap $28.15B). The key difference: Novartis AG is far larger — about 9.5× Williams-Sonoma, Inc.'s market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Williams-Sonoma, Inc. for 59 Days on average.
| NVS | WSM | |
|---|---|---|
Market Cap | $268.57B | $28.15B |
Volume | 1,532,573 | 1,351,262 |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $251.81 |
52-Week Low | $121.80 | $168.64 |
Typical Hold Time | 82 Days | 59 Days |
Enterprise Value | $309.89B | $28.65B |
Dividend Yield | 3.31% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.75, up 0.33% on the day, near the consensus price target of $146.00. Recent earnings show mixed quarterly beats and a miss in Q1 2026, with revenue growth to $56.67B in 2025 and a net income margin of 24.67%. Technical indicators signal a bearish trend, while analyst sentiment is mixed with 24% buy ratings. The company recently announced a $7.8B licensing deal with China's Abogen for mRNA therapy, but faces scrutiny over clinical setbacks and M&A strategy.
The outlook for NVS hinges on execution of its pipeline and deal integration amid investor caution. Opportunities include expansion into autoimmune treatments and solid profitability, but risks involve trial failures, regulatory probes, and debt levels rising to 30.26% of assets. Wall Street remains neutral with a slight upside to the price target.
Williams-Sonoma (WSM) trades at $241.78, up 0.55% on the day, reflecting strong momentum near its consensus price target of $246.31. The stock exhibits a bullish technical trend, supported by robust fundamentals including a 14.73% net income margin and consistent earnings beats in recent quarters. Recent news highlights market share gains and profitability improvements, with the company raising full-year guidance after strong Q2 2026 results.
The outlook remains positive given WSM's operational efficiency and dividend growth, though risks include housing market sensitivity and competitive pressures. Analyst consensus leans bullish with 32% buy ratings, but high valuation multiples like a P/E of 24.51 warrant caution amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
